Darunavir

Paul A. Pham, Pharm.D., Janessa M. Smith, Pharm.D. BCPS, Alice Jenh Hsu, Pharm.D.
Darunavir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • HIV-infected patients who are treatment-experienced and have at least one DRV resistance mutation, in combination with other antiretrovirals (DRV/r 600/100 mg twice daily).
  • HIV-infected patients who are treatment-naive (DRV/r 800/100 mg once daily or DRV/c 800/150 mg once daily).
  • HIV-infected children (>3 years)

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: January 12, 2016

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Darunavir ID - 540156 A1 - Hsu,Alice,Pharm.D. AU - Pham,Paul,Pharm.D. AU - Smith,Janessa,Pharm.D. BCPS Y1 - 2016/01/12/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540156/all/Darunavir PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -